Granting-In-Part Patent Owner's Motion to Expunge
37 C.F.R. secs. 42.14, 42.56 | Aug 29, 2019 | PAPER | BOARD |
Patent Owners Motion to Expunge Under 37 C.F.R. 42.56 | Jul 16, 2019 | PAPER | PATENT OWNER |
Patent Owner's Notice of Appeal | Dec 19, 2018 | PAPER | PATENT OWNER |
Decision Denying Patent Owner's Request for Rehearing | Dec 3, 2018 | PAPER | BOARD |
Panel Change Order | Sep 28, 2018 | PAPER | BOARD |
Updated Mandatory Notices | Jul 23, 2018 | PAPER | PETITIONER |
Patent Owners Request for Rehearing | Feb 16, 2018 | PAPER | PATENT OWNER |
Final Written Decision | Jan 17, 2018 | PAPER | BOARD |
Record of Oral Hearing | Jun 23, 2017 | PAPER | BOARD |
Patent Owners Reply in Support of Its Motion to Exclude Evidence Pursuant to 37 C.F.R 42.64(c) | May 19, 2017 | PAPER | PATENT OWNER |
ORDER TRIAL HEARING | May 15, 2017 | PAPER | BOARD |
Supplemental Declaration of Declaration of Paul A. Godley, M.D., Ph.D., MPP | May 12, 2017 | EXHIBIT | PETITIONER |
Second Supplemental Declaration of Robert D. Stoner, Ph.D. | May 12, 2017 | EXHIBIT | PETITIONER |
Replacement of WCK1112 | May 12, 2017 | EXHIBIT | PETITIONER |
Petitioner's Opposition to Patent Owner's Motion to Exclude Evidence | May 12, 2017 | PAPER | PETITIONER |
Petitioner's Updated Exhibit List | May 12, 2017 | PAPER | PETITIONER |
Declaration of Lestin L. Kenton Jr. | May 12, 2017 | EXHIBIT | PETITIONER |
Replacement of WCK1090 | May 12, 2017 | EXHIBIT | PETITIONER |
Replacement of WCK1128 | May 12, 2017 | EXHIBIT | PETITIONER |
Supplemental Declaration of Paul A. Godley, M.D., Ph.D., MPP | May 12, 2017 | EXHIBIT | PETITIONER |
Supplemental to WCK1070 | May 12, 2017 | EXHIBIT | PETITIONER |
Supplemental Declaration of Robert D. Stoner, Ph.D. | May 12, 2017 | EXHIBIT | PETITIONER |
Petitioner's Response to Patent Owner's Motion for Observations on Cross-Examination of Petitioner's Reply Witnesses | May 12, 2017 | PAPER | PETITIONER |
Patent Owner's Request for Oral Argument | May 5, 2017 | PAPER | PATENT OWNER |
Patent Owners Motion to Exclude Evidence Pursuant to 37 C.F.R. 42.64c | May 5, 2017 | PAPER | PATENT OWNER |
JSN 2187 | May 5, 2017 | EXHIBIT | PATENT OWNER |
JSN 2177 | May 5, 2017 | EXHIBIT | PATENT OWNER |
JSN 2183 | May 5, 2017 | EXHIBIT | PATENT OWNER |
JSN 2184 | May 5, 2017 | EXHIBIT | PATENT OWNER |
JSN 2185 | May 5, 2017 | EXHIBIT | PATENT OWNER |
JSN 2186 | May 5, 2017 | EXHIBIT | PATENT OWNER |
Patent Owners Motion for Observation on Cross-Examination | May 5, 2017 | PAPER | PATENT OWNER |
Janssen Oncology Inc.s Updated Exhibit List | May 5, 2017 | PAPER | PATENT OWNER |
Petitioner's Request for Oral Hearing | May 3, 2017 | PAPER | PETITIONER |
Decision - Unopposed Motion to Withdraw - 37 CFR 42.10(e) | Apr 26, 2017 | PAPER | BOARD |
Patent Owners Objections to Evidence | Apr 26, 2017 | PAPER | PATENT OWNER |
Patent Owners Notice of Deposition of Paul A. Godley, M.D., Ph.D., M.P.P. | Apr 21, 2017 | PAPER | PATENT OWNER |
Petitioner's Motion to Withdraw Back-Up Counsel and Substitute New Back-Up Counsel | Apr 21, 2017 | PAPER | PETITIONER |
Patent Owner¿¿¿s Notice of Deposition of Robert D. Stoner, Ph.D. | Apr 20, 2017 | PAPER | PATENT OWNER |
Decision on Motion for Pro Hac Vice Admission of Alyssa B. Monsen | Apr 19, 2017 | PAPER | BOARD |
Petitioner's Motion to Seal | Apr 19, 2017 | PAPER | PETITIONER |
EXPUNGED | Apr 19, 2017 | EXHIBIT | PETITIONER |
EXPUNGED | Apr 19, 2017 | EXHIBIT | PETITIONER |
Montgomery 2016 | Apr 19, 2017 | EXHIBIT | PETITIONER |
Nishimura 2000 | Apr 19, 2017 | EXHIBIT | PETITIONER |
"BTG Licenses New Prostate Cancer Drug to Cougar Biotechnology," | Apr 19, 2017 | EXHIBIT | PETITIONER |
Auchus 2001 | Apr 19, 2017 | EXHIBIT | PETITIONER |
Deposition Transcript of Ian Judson, M.D., Friday, April 7, 2017 | Apr 19, 2017 | EXHIBIT | PETITIONER |
Attard 2012 | Apr 19, 2017 | EXHIBIT | PETITIONER |
Akakura 2003 | Apr 19, 2017 | EXHIBIT | PETITIONER |
Updated Curriculum Vitae for Dr. Robert D. Stoner | Apr 19, 2017 | EXHIBIT | PETITIONER |
Deposition Transcript of Christopher A. Vellturo, Ph.D., Wednesday, April 5, 2017 | Apr 19, 2017 | EXHIBIT | PETITIONER |
Cancer Research UK, "Our milestones: the birth of a new prostate cancer drug," | Apr 19, 2017 | EXHIBIT | PETITIONER |
Auchus 2014 | Apr 19, 2017 | EXHIBIT | PETITIONER |
Attard 2016 | Apr 19, 2017 | EXHIBIT | PETITIONER |
Ryan 2010 | Apr 19, 2017 | EXHIBIT | PETITIONER |
Reid 2010 | Apr 19, 2017 | EXHIBIT | PETITIONER |
Deposition Transcript of Matthew B. Rettig, M.D., Friday, March 31, 2017 | Apr 19, 2017 | EXHIBIT | PETITIONER |
Second Declaration of Paul A. Godley, MD, Ph.D., MPP | Apr 19, 2017 | EXHIBIT | PETITIONER |
Mohler 2004 | Apr 19, 2017 | EXHIBIT | PETITIONER |
The Institute of Cancer Research, "Abiraterone: a story of scientific innovation and commercial partnership," | Apr 19, 2017 | EXHIBIT | PETITIONER |
Updated Curriculum Vitae for Paul A. Godley, MD, Ph.D., MPP | Apr 19, 2017 | EXHIBIT | PETITIONER |
Declaration of Ian McKeague, Ph.D | Apr 19, 2017 | EXHIBIT | PETITIONER |
NCT0205010 | Apr 19, 2017 | EXHIBIT | PETITIONER |
EMA ¿¿¿ Zytiga Product Information | Apr 19, 2017 | EXHIBIT | PETITIONER |
Storlie 1995 | Apr 19, 2017 | EXHIBIT | PETITIONER |
Deposition Transcript of Richard Auchus, M.D., Ph.D., Thursday, December 15, 2016 (IPR2016-00286) | Apr 19, 2017 | EXHIBIT | PETITIONER |
Canger.gov (NIH NCI) | Apr 19, 2017 | EXHIBIT | PETITIONER |
Mestre-Ferrandiz 2012 | Apr 19, 2017 | EXHIBIT | PETITIONER |
DiMasi 2016 | Apr 19, 2017 | EXHIBIT | PETITIONER |
Zytiga¿¿ Approved in the EU for Use in the Treatment of Metastatic Castration-Resistant Prostate Cancer Before Chemotherapy | Apr 19, 2017 | EXHIBIT | PETITIONER |
Dizdar 2015 | Apr 19, 2017 | EXHIBIT | PETITIONER |
David 2005 | Apr 19, 2017 | EXHIBIT | PETITIONER |
Cancer.org (ACS) | Apr 19, 2017 | EXHIBIT | PETITIONER |
Auerbauch U.S. Pat. Appl. Publ. No. 2015/0005268 | Apr 19, 2017 | EXHIBIT | PETITIONER |
Deposition Transcript of Richard J. Auchus, M.D., Ph.D., Monday, April 10, 2017 (Redacted) | Apr 19, 2017 | EXHIBIT | PETITIONER |
Declaration of Matthew B. Rettig, M.D. (submitted in IPR2016-00286) | Apr 19, 2017 | EXHIBIT | PETITIONER |
Declaration of Matthew B. Rettig, M.D. (submitted in IPR2016-01332) | Apr 19, 2017 | EXHIBIT | PETITIONER |
Petitioner's Updated Mandatory Notices | Apr 19, 2017 | PAPER | PETITIONER |
Cougar Biotechnology, Inc. | Apr 19, 2017 | EXHIBIT | PETITIONER |
Deposition Transcript of Christopher A. Vellturo, Ph.D., Tuesday, December 20, 2016 (IPR2016-00286) | Apr 19, 2017 | EXHIBIT | PETITIONER |
Second Declaration of Robert D. Stoner, Ph.D. (Redacted) | Apr 19, 2017 | EXHIBIT | PETITIONER |
Declaration of Marc B. Garnick, M.D. (submitted in IPR2016-01332) | Apr 19, 2017 | EXHIBIT | PETITIONER |
Petitioner's Updated Exhibit List | Apr 19, 2017 | PAPER | PETITIONER |
Petitioner's Reply to Patent Owner Response | Apr 19, 2017 | PAPER | PETITIONER |
Janssen Oncology, Inc.s Motion for Pro Hac Vice Admission of Alyssa B. Monsen | Apr 3, 2017 | PAPER | PATENT OWNER |
JSN 2169 Declaration of Alyssa B. Monsen | Apr 3, 2017 | EXHIBIT | PATENT OWNER |
Petitioner's Notice of Deposition of Richard Auchus, M.D., Ph.D. | Mar 27, 2017 | PAPER | PETITIONER |
Petitioner's Objections to Patent Owner's Evidence | Mar 24, 2017 | PAPER | PETITIONER |
Petitioner's Notice of Deposition of Matthew Rettig, M.D. | Mar 24, 2017 | PAPER | PETITIONER |
Petitioner's Notice of Deposition of Christopher A. Vellturo, Ph.D. | Mar 24, 2017 | PAPER | PETITIONER |
Petitioner's Notice of Deposition of Ian Judson, M.D. | Mar 24, 2017 | PAPER | PETITIONER |
Petitioner's Notice of Deposition of Christopher A. Vellturo, Ph.D. | Mar 22, 2017 | PAPER | PETITIONER |
JSN 2012 PM Live Top 50 Pharmaceuticals | Mar 17, 2017 | EXHIBIT | PATENT OWNER |
JSN 2014 Johnson & Johnson Press Release 1/24/2017 | Mar 17, 2017 | EXHIBIT | PATENT OWNER |
JSN 2015 Declaration of Dr. Marc Garnick | Mar 17, 2017 | EXHIBIT | PATENT OWNER |
JSN 2013 Johnson & Johnson Press Release 1/26/2016 | Mar 17, 2017 | EXHIBIT | PATENT OWNER |
JSN 2016 Deposition Transcript of Marc B. Garnick, M.D., taken by Patent Owner on February 16, 2017 | Mar 17, 2017 | EXHIBIT | PATENT OWNER |
JSN 2017 Declaration of Scott Serels, MD, filed on Dec. 4, 2015 in Amerigen Pharmaceuticals Ltd. v. Janssen Oncology, Inc., IPR2016-00286. | Mar 17, 2017 | EXHIBIT | PATENT OWNER |
JSN 2020 Deposition Transcript of Scott Serels, M.D., taken by Patent Owner on August 22, 2016 in Amerigen Pharmaceuticals Ltd. v. Janssen Oncology, Inc., IPR2016-00286 | Mar 17, 2017 | EXHIBIT | PATENT OWNER |
JSN 2023 Herr and Pfitzenmaier, ¿¿¿Glucocorticoid use in prostate cancer and other solid tumours: implications for effectiveness of cytotoxic
treatment and metastases,¿¿¿ The Lancet, 7:425-430 (2006) | Mar 17, 2017 | EXHIBIT | PATENT OWNER |
JSN 2024 Krishnan et al., ¿¿¿A Glucocorticoid-Responsive Mutant Androgen Receptor Exhibits Unique Ligand Specificity: Therapeutic
Implications for Androgen-Independent Prostate Cancer,¿¿¿ Endocrinology, 145:1889-1900 (2002) | Mar 17, 2017 | EXHIBIT | PATENT OWNER |
JSN 2027 Rumohr and Chang, ¿¿¿Current chemotherapeutic approaches for androgen-independent prostate cancer,¿¿¿ Current Opinion in Investigational Drugs, 7(6):529-533 (2006) | Mar 17, 2017 | EXHIBIT | PATENT OWNER |
JSN 2029 Judson CV | Mar 17, 2017 | EXHIBIT | PATENT OWNER |
JSN 2031 Burgess and Roth, ¿¿¿Changing Perspectives of the Role of Chemotherapy in Advanced Prostate Cancer,¿¿¿ Urol. Clin. N. Am., 33:227-236 (2006) | Mar 17, 2017 | EXHIBIT | PATENT OWNER |
JSN 2032 Strother et al., ¿¿¿Novel cytotoxic and biological agents for prostate cancer: Where will the money be in 2005?,¿¿¿ European Journal of Cancer, 41:954-964 (2005) | Mar 17, 2017 | EXHIBIT | PATENT OWNER |
JSN 2034 Press Release 1/21/2014 | Mar 17, 2017 | EXHIBIT | PATENT OWNER |
JSN 2036 Hadaschik et al., ¿¿¿Novel targets and approaches in advanced prostate cancer,¿¿¿ Current Opinions Urology, 17:182-187 (2007) | Mar 17, 2017 | EXHIBIT | PATENT OWNER |
JSN 2018 Deposition Transcript of Scott R. Serels, taken by Patent Owner on January 21, 2017 in Amerigen Pharmaceuticals Ltd. v. Janssen Oncology, Inc., IPR2016-00286. | Mar 17, 2017 | EXHIBIT | PATENT OWNER |
JSN 2019 Declaration of Scott Serels, MD, filed on Jan. 16, 2017 in Amerigen Pharmaceuticals Ltd. v. Janssen Oncology, Inc., IPR2016-00286. | Mar 17, 2017 | EXHIBIT | PATENT OWNER |
JSN 2021 Boumpas et al., ¿¿¿Glucocorticoid Therapy for Immune-mediated Diseases: Basic and Clinical Correlates,¿¿¿ Ann. Internal Medicine, 119:1198-1208 (1993) | Mar 17, 2017 | EXHIBIT | PATENT OWNER |
JSN 2022 Debruyne and Witjes, ¿¿¿Ketoconazole High Dose (H.D.) In The Management Of Metastatic Prostatic Carcinoma,¿¿¿ The Journal of Urology, 135(4, pt.2):203A, Abstract 397 (1986) | Mar 17, 2017 | EXHIBIT | PATENT OWNER |
JSN 2025 Conde and Aronson, ¿¿¿Risk factors for male osteoporosis,¿¿¿ Urologic Oncology, 21:380-383 (2003) | Mar 17, 2017 | EXHIBIT | PATENT OWNER |
JSN 2026 Remington ¿¿¿ The Science and Practice of Pharmacy, 20th ed., pp. 1363-1370 (2000) | Mar 17, 2017 | EXHIBIT | PATENT OWNER |
JSN 2028 Declaration of Professor Ian Judson, M.D. | Mar 17, 2017 | EXHIBIT | PATENT OWNER |
JSN 2030 Clinical Cancer Research Peer Review letter to Judson, dated May 12, 2003 | Mar 17, 2017 | EXHIBIT | PATENT OWNER |
JSN 2035 Press Release 1/20/2015 | Mar 17, 2017 | EXHIBIT | PATENT OWNER |
JSN 2038 Declaration of Matthew Rettig, M.D. | Mar 17, 2017 | EXHIBIT | PATENT OWNER |
Petitioner's Notice of Deposition of Matthew Rettig, M.D. | Mar 17, 2017 | PAPER | PETITIONER |
JSN 2039 Rettig CV | Mar 17, 2017 | EXHIBIT | PATENT OWNER |
JSN 2040 Declaration of Richard Auchus, M.D., Ph.D. | Mar 17, 2017 | EXHIBIT | PATENT OWNER |
JSN 2041 Auchus CV | Mar 17, 2017 | EXHIBIT | PATENT OWNER |
JSN 2046 Therasse et al., ¿¿¿New Guidelines to Evaluate the Response to Treatment in Solid Tumors,¿¿¿ J. Natl Cancer Inst., 92:205-216 (2000) | Mar 17, 2017 | EXHIBIT | PATENT OWNER |
JSN 2048 Altman et al., ¿¿¿The Revised CONSORT Statement for Reporting Randomized Trials: Explanation and Elaboration,¿¿¿ Ann. Intern. Med., 134:663-694 (2001) | Mar 17, 2017 | EXHIBIT | PATENT OWNER |
JSN 2042 Papatsoris et al., ¿¿¿Novel Biological Agents for the Treatment of Hormone-Refractory Prostate Cancer (HRPC),¿¿¿ Current Medicinal Chemistry, 12:277-296 (2005) | Mar 17, 2017 | EXHIBIT | PATENT OWNER |
JSN 2043 Armstrong and Carducci, ¿¿¿New drugs in prostate cancer,¿¿¿ Current Opinions Urology, 16:138-145 (2006) | Mar 17, 2017 | EXHIBIT | PATENT OWNER |
EXPUNGED | Mar 17, 2017 | EXHIBIT | PATENT OWNER |
JSN 2045 Vellturo CV | Mar 17, 2017 | EXHIBIT | PATENT OWNER |
JSN 2047 Stamey et al., ¿¿¿Prostate-Specific Antigen As A Serum Marker For Adenocarcinoma Of The Prostate,¿¿¿ NEJM, 317(15):909-916 (1987) | Mar 17, 2017 | EXHIBIT | PATENT OWNER |
JSN 2049 Blackard, ¿¿¿Letters to the Editor,¿¿¿ Journal of Urology, 146(6):1621-1622 (1991) | Mar 17, 2017 | EXHIBIT | PATENT OWNER |
JSN 2050 MedlinePlus, ¿¿¿ACTH stimulation test,¿¿¿ available at https://medlineplus.gov/ency/article/003696.htm, last visited Sept. 30, 2016 | Mar 17, 2017 | EXHIBIT | PATENT OWNER |
JSN 2052 Grinspoon and Biller, ¿¿¿Clinical Review 62 Laboratory Assessment of Adrenal Insufficiency,¿¿¿ J. Clin. Endocrinol. And Metabolism, 79(4):923-931 (1994) | Mar 17, 2017 | EXHIBIT | PATENT OWNER |
JSN 2053 Lara and Meyers, ¿¿¿Treatment Options in Androgen-Independent Prostate Cancer,¿¿¿ Cancer Investigation, 17(2):137-144 (1999) | Mar 17, 2017 | EXHIBIT | PATENT OWNER |
JSN 2054 Kuzel et al., ¿¿¿A Phase II Study of Continuous Infusion 5-Fluorouracil in Advanced Hormone Refractory Prostate Cancer,¿¿¿ Cancer, 72(6):1965-1968 (1993) | Mar 17, 2017 | EXHIBIT | PATENT OWNER |
JSN 2056 Sternberg, ¿¿¿Hormone refractory metastatic prostate cancer,¿¿¿ Annals of Oncology, 3:331-335 (1992) | Mar 17, 2017 | EXHIBIT | PATENT OWNER |
JSN 2058 Excerpts from Seifter, Concepts in Medical Physiology, Chapter 34, pp. 540-553, Chapter 37, pp. 606-620 (2005) | Mar 17, 2017 | EXHIBIT | PATENT OWNER |
JSN 2059 Petrylak et al., ¿¿¿Docetaxel and Estramustine Compared with Mitoxantrone and Prednisone for Advanced Refractory Prostate Cancer,¿¿¿ NEJM, 351:1513-1520 (2004) | Mar 17, 2017 | EXHIBIT | PATENT OWNER |
JSN 2063 Small et al., ¿¿¿Antiandrogen Withdrawal Alone or in Combination With Ketoconazole in Androgen-Independent Prostate Cancer Patients: A Phase III Trial (CALGB 9583),¿¿¿ J. Clin. Oncology, 22(6):1025-1033 (2004) | Mar 17, 2017 | EXHIBIT | PATENT OWNER |
JSN 2066 Mantero et al., ¿¿¿Long-term treatment of mineralocorticoid excess syndromes,¿¿¿ Steroids, 60:81-86 (1995)- | Mar 17, 2017 | EXHIBIT | PATENT OWNER |
JSN 2051 Dorin et al., ¿¿¿Diagnosis of Adrenal Insufficiency,¿¿¿ Ann. Inern. Med., 139:194-204 (2003) | Mar 17, 2017 | EXHIBIT | PATENT OWNER |
JSN 2055 Scher et al., ¿¿¿Bicalutamide for Advanced Prostate Cancer: The Natural Versus Treated History of Disease,¿¿¿ J. Clin. Oncology, 15:2928-2838 (1997) | Mar 17, 2017 | EXHIBIT | PATENT OWNER |
JSN 2057 Bubley et al., ¿¿¿Eligibility and Response Guidelines for Phase II Clinical Trials in Androgen-Independent Prostate Cancer: Recommendations From the Prostate-Specific Antigen Working Group,¿¿¿ J. Clin. Oncology, 17:3461-3467 (1999) | Mar 17, 2017 | EXHIBIT | PATENT OWNER |
JSN 2060 Marini et al., ¿¿¿The effect of adjuvant prednisone combined with CMF on patterns of relapse and occurrence of second malignancies in patients with breast cancer,¿¿¿ Annals of Oncology, 7:245-250 (1996) | Mar 17, 2017 | EXHIBIT | PATENT OWNER |
JSN 2061 Body, ¿¿¿Low-dose prednisone and increased risk of development of bone metastases,¿¿¿ Annals of Oncology, 7:643-645 (1996) | Mar 17, 2017 | EXHIBIT | PATENT OWNER |
JSN 2062 Craft, ¿¿¿Eplerenone (Inspra), a new aldosterone antagonist for the treatment of systemic hypertension and heart failure,¿¿¿ BUMC Proceedings, 17:217-220 (2004) | Mar 17, 2017 | EXHIBIT | PATENT OWNER |
JSN 2064 Millikan, et al., ¿¿¿Randomized phase 2 trial of ketoconazole and ketoconazole/doxorubicin in androgen independent prostate cancer,¿¿¿ Urologic Oncology, 6:111-115 (2001) | Mar 17, 2017 | EXHIBIT | PATENT OWNER |
JSN 2065 Farwell, et al., ¿¿¿Total Suppression of Cortisol Excretion by Ketoconazole in the Therapy of the Ectopic Adrenocorticotropic Hormone Syndrome,¿¿¿ American Journal of Medicine, 84:1063-1066 (1988) | Mar 17, 2017 | EXHIBIT | PATENT OWNER |
JSN 2067 Palmer, ¿¿¿Managing Hyperkalemia Caused by Inhibitors of the Renin¿¿¿Angiotensin¿¿¿Aldosterone System,¿¿¿ NEJ, 351:585-592 (2004) | Mar 17, 2017 | EXHIBIT | PATENT OWNER |
JSN 2068 Swartz and Dluhy, ¿¿¿Corticosteroids: Clinical Pharmacology and Therapeutic Use,¿¿¿ Drugs, 16:238-255 (1978) | Mar 17, 2017 | EXHIBIT | PATENT OWNER |
JSN 2069 Seale and Compton, ¿¿¿Side-effects of corticosteroid agents,¿¿¿, Med. J. of Australia, 144(3):139-142 (1986) | Mar 17, 2017 | EXHIBIT | PATENT OWNER |
JSN 2070 FDA Press Release (2011) | Mar 17, 2017 | EXHIBIT | PATENT OWNER |
JSN 2071 Ryan et al., ¿¿¿Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer | Mar 17, 2017 | EXHIBIT | PATENT OWNER |
JSN 2072 Booth et al., ¿¿¿Oncology¿¿¿s trials,¿¿¿ Nature Reviews, 2:609-610 (2003) | Mar 17, 2017 | EXHIBIT | PATENT OWNER |
JSN 2074 Active/Ipsen April 16, 2015 Press Release | Mar 17, 2017 | EXHIBIT | PATENT OWNER |
JSN 2075 Takeda June 19, 2014 Press Release | Mar 17, 2017 | EXHIBIT | PATENT OWNER |
JSN 2076 Michaelson et al., ¿¿¿Randomized, Placebo-Controlled, Phase III Trial of Sunitinib Plus Prednisone Versus Prednisone Alone in Progressive, Metastatic, Castration-Resistant Prostate Cancer,¿¿¿ J. Clin. Oncology, 31:1-8 (2013) | Mar 17, 2017 | EXHIBIT | PATENT OWNER |
JSN 2081 Genentech March 12, 2010 Press Release | Mar 17, 2017 | EXHIBIT | PATENT OWNER |
JSN 2083 Novacea Form 8-K at 1.02 | Mar 17, 2017 | EXHIBIT | PATENT OWNER |
JSN 2085 Sephton, et al., ¿¿¿Diurnal Cortisol Rhythm as a Predictor of Breast Cancer Survival,¿¿¿ Journal of National Cancer Institute, 92(12):994-1000 (2000) | Mar 17, 2017 | EXHIBIT | PATENT OWNER |
JSN 2073 Tokai July 26, 2016 Press Release | Mar 17, 2017 | EXHIBIT | PATENT OWNER |
JSN 2077 OncoGenex (April 28, 2014) Press Release | Mar 17, 2017 | EXHIBIT | PATENT OWNER |
JSN 2078 BMS Sept. 12, 2013 Press Release | Mar 17, 2017 | EXHIBIT | PATENT OWNER |
JSN 2079 Carducci et al., ¿¿¿A Phase 3 Randomized Controlled Trial of the Efficacy and Safety of Atrasentan in Men With Metastatic Hormone-refractory Prostate Cancer,¿¿¿ Cancer, 110(9):1959-1966 (2007) | Mar 17, 2017 | EXHIBIT | PATENT OWNER |
JSN 2080 Antonarakis and Eisenberger, ¿¿¿Phase III Trials With Docetaxel-Based Combinations for Metastatic Castration-Resistant Prostate Cancer: Time to Learn From Past Experiences,¿¿¿ J. Clin. Oncology, 31(14):1709-1712 (2013) | Mar 17, 2017 | EXHIBIT | PATENT OWNER |
JSN 2082 Mulcahy, Medscape October 17, 2008 Press Release | Mar 17, 2017 | EXHIBIT | PATENT OWNER |
JSN 2084 ImmunoGen, Inc. Form 8-K, Item 8.01 | Mar 17, 2017 | EXHIBIT | PATENT OWNER |
JSN 2087 White, P.C., ¿¿¿Synthesis and Metabolism of Corticosteroids,¿¿¿ Principles and Practice of Endocrinology and Metabolism, Ed. Kenneth L. Becker, Philadelphia: Lippincott Williams & Wilkins, 2001, Chapter 73, 714-719 | Mar 17, 2017 | EXHIBIT | PATENT OWNER |
JSN 2089 NCI - SEER Stat Fact Sheets: Prostate Cancer | Mar 17, 2017 | EXHIBIT | PATENT OWNER |
JSN 2086 White, P.C., ¿¿¿Synthesis and Metabolism of Corticosteroids,¿¿¿ Principles and Practice of Endocrinology and Metabolism, Ed. Kenneth L. Becker, Philadelphia: Lippincott Williams & Wilkins, 2001, Chapter 72, 704-714 | Mar 17, 2017 | EXHIBIT | PATENT OWNER |
JSN 2088 White, P.C., ¿¿¿Synthesis and Metabolism of Corticosteroids,¿¿¿ Principles and Practice of Endocrinology and Metabolism, Ed. Kenneth L. Becker, Philadelphia: Lippincott Williams & Wilkins, 2001, Chapter 78, 751-764 | Mar 17, 2017 | EXHIBIT | PATENT OWNER |
EXPUNGED | Mar 17, 2017 | EXHIBIT | PATENT OWNER |
JSN 2095 Zytiga Usage ¿¿¿ prednisone information | Mar 17, 2017 | EXHIBIT | PATENT OWNER |
JSN 2098 ACS ¿¿¿ ¿¿¿What is Prostate Cancer? Topics¿¿¿ | Mar 17, 2017 | EXHIBIT | PATENT OWNER |
JSN 2099 Cancer.Net - September 8, 2014 ¿¿¿Treatment of Metastatic Castration Resistant Prostate Cancer¿¿¿ | Mar 17, 2017 | EXHIBIT | PATENT OWNER |
JSN 2101 J&J May 21, 2009 Press Release | Mar 17, 2017 | EXHIBIT | PATENT OWNER |
JSN 2090 Tucker et al., ¿¿¿Reversible Adrenal Insufficiency Induced by Ketoconazole,¿¿¿ JAMA, 253(16):2413-2414 (1985) | Mar 17, 2017 | EXHIBIT | PATENT OWNER |
JSN 2091 What You Need to Know About Prostate Cancer, NIH Publication No. 12-1576 (2012) | Mar 17, 2017 | EXHIBIT | PATENT OWNER |
EXPUNGED | Mar 17, 2017 | EXHIBIT | PATENT OWNER |
JSN 2096 Zytiga Usage ¿¿¿ total promotional spend | Mar 17, 2017 | EXHIBIT | PATENT OWNER |
JSN 2100 CDC ¿¿¿ ¿¿¿Prostate Cancer¿¿¿ | Mar 17, 2017 | EXHIBIT | PATENT OWNER |
JSN 2102 Mayo Clinic ¿¿¿ Prednisone and other corticosteroids | Mar 17, 2017 | EXHIBIT | PATENT OWNER |
JSN 2104 NCI ¿¿¿ Docetaxel | Mar 17, 2017 | EXHIBIT | PATENT OWNER |
JSN 2106 Orange Book ¿¿¿ Xofigo | Mar 17, 2017 | EXHIBIT | PATENT OWNER |
JSN 2107 Orange Book ¿¿¿ Xtandi | Mar 17, 2017 | EXHIBIT | PATENT OWNER |
JSN 2109 Hotte and Saad, ¿¿¿Current management of castrate-resistant prostate cancer,¿¿¿ Current Oncology, 17(2):S72-S79 (2010) | Mar 17, 2017 | EXHIBIT | PATENT OWNER |
JSN 2110 J&J January 22, 2013 Press Release ¿¿¿ Johnson & Johnson Reports 2012 Fourth-Quarter and Full-Year Results | Mar 17, 2017 | EXHIBIT | PATENT OWNER |
JSN 2112 Boehringer-Ingelheim-BTG Press Release ¿¿¿ ¿¿¿NEW TREATMENT FOR PROSTATE CANCER UNDER DEVELOPMENT,¿¿¿ dated May 22, 1996 | Mar 17, 2017 | EXHIBIT | PATENT OWNER |
JSN 2113 Public Citizen Press Room Release ¿¿¿ ¿¿¿Antifungal Treatment Should Be Taken Off the Market, Public Citizen Tells FDA,¿¿¿ dated February 24, 2015. | Mar 17, 2017 | EXHIBIT | PATENT OWNER |
JSN 2114 Williams et al., ¿¿¿Objective Responses to Ketoconazole Therapy in Patients with Relapsed Progressive Prostatic Cancer,¿¿¿ British Journal of Urology, 58:45-51 (1986). | Mar 17, 2017 | EXHIBIT | PATENT OWNER |
JSN 2116 Williams, ¿¿¿Discontinued Drugs in 2007: oncology drugs,¿¿¿ Expert Opinion on Investigational Drugs, 17(12):1791-1816 (2008) | Mar 17, 2017 | EXHIBIT | PATENT OWNER |
EXPUNGED | Mar 17, 2017 | EXHIBIT | PATENT OWNER |
JSN 2103 Medical Dictionary ¿¿¿ refractory cancer | Mar 17, 2017 | EXHIBIT | PATENT OWNER |
JSN 2105 NCI ¿¿¿ Metastatic Cancer | Mar 17, 2017 | EXHIBIT | PATENT OWNER |
JSN 2108 Orange Book ¿¿¿ Jevtana | Mar 17, 2017 | EXHIBIT | PATENT OWNER |
JSN 2111 Duc et al., ¿¿¿In vitro and in vivo models for the evaluation of potent inhibitors of male rat for the 17¿¿-hydroxylase/C17,20-lyase,¿¿¿ Journal of Steroid Biochemistry & Molecular Biology, 84:537-542 (2003). | Mar 17, 2017 | EXHIBIT | PATENT OWNER |
JSN 2115 Redacted Expert Report of Christopher Vellturo | Mar 17, 2017 | EXHIBIT | PATENT OWNER |
JSN 2117 Williams, ¿¿¿Discontinued Drugs in 2008: oncology drugs,¿¿¿ Expert Opinion on Investigational Drugs, 18(11):1581-1594 (2009) | Mar 17, 2017 | EXHIBIT | PATENT OWNER |
JSN 2129 Eplerenone Label | Mar 17, 2017 | EXHIBIT | PATENT OWNER |
JSN 2124 Deposition Transcript of Mark J. Ratain, M.D., taken by Patent Owner on January 23, 2017 in Amerigen Pharmaceuticals Ltd. v. Janssen Oncology, Inc., IPR2016-00286. | Mar 17, 2017 | EXHIBIT | PATENT OWNER |
JSN 2125 Deposition Transcript of Richard Dorin, M.D., taken by Patent Owner on January 19, 2017 in Amerigen Pharmaceuticals Ltd. v. Janssen Oncology, Inc., IPR2016-00286. | Mar 17, 2017 | EXHIBIT | PATENT OWNER |
JSN 2128 Deposition Transcript of Ivan T. Hofmann, taken by Patent Owner on February 7, 2017 | Mar 17, 2017 | EXHIBIT | PATENT OWNER |
JSN 2130 Academy of Managed Care Pharmacy (AMCP) Nexus 2016 Poster | Mar 17, 2017 | EXHIBIT | PATENT OWNER |
JSN 2131 Van den Akker et al., ¿¿¿Differential Inhibition of 17a-Hydroxylase and 17,20-Lyase Activities by Three Novel Missense CYP17
Mutations Identified in Patients with P450c17 Deficiency,¿¿¿ J. Clin. Endocrinol. & Metabolism, 87(12):5714-5721 (2002) | Mar 17, 2017 | EXHIBIT | PATENT OWNER |
JSN 2132 Order Granting Janssen¿¿¿s Motion to Set a Hearing and Correct Inventorship of the ¿¿¿438 Patent | Mar 17, 2017 | EXHIBIT | PATENT OWNER |
JSN 2133 Ryan, et al., ¿¿¿Phase I Clinical Trial of the CYP17 Inhibitor Abiraterone Acetate Demonstrating Clinical Activity in Patients With Castration-Resistant Prostate Cancer | Mar 17, 2017 | EXHIBIT | PATENT OWNER |
JSN 2134 ZYTIGA Market Share data | Mar 17, 2017 | EXHIBIT | PATENT OWNER |
JSN 2137 BTG Annual Report, 2003 | Mar 17, 2017 | EXHIBIT | PATENT OWNER |
JSN 2139 J&J Q1 2013 Earnings Call Transcript | Mar 17, 2017 | EXHIBIT | PATENT OWNER |
JSN 2135 Truven Commercial and Medicare Data | Mar 17, 2017 | EXHIBIT | PATENT OWNER |
JSN 2136 BTG Webpage from WayBack Machine | Mar 17, 2017 | EXHIBIT | PATENT OWNER |
JSN 2138 BTG Annual Report, 2004 | Mar 17, 2017 | EXHIBIT | PATENT OWNER |
JSN 2142 J&J Q4 2013 Earnings Call Transcript | Mar 17, 2017 | EXHIBIT | PATENT OWNER |
JSN 2144 J&J Q2 2014 Earnings Call Transcript | Mar 17, 2017 | EXHIBIT | PATENT OWNER |
JSN 2149 J&J Q3 2015 Earnings Call Transcript | Mar 17, 2017 | EXHIBIT | PATENT OWNER |
JSN 2158 ECOG Performance Status,¿¿¿ | Mar 17, 2017 | EXHIBIT | PATENT OWNER |
JSN 2160 Deposition Transcript of Robert D. Stoner, taken by Patent Owner on February 10, 2017 | Mar 17, 2017 | EXHIBIT | PATENT OWNER |
JSN 2164 July 3, 2013 Notice of Allowance from prosecution history of
¿¿¿438 patent | Mar 17, 2017 | EXHIBIT | PATENT OWNER |
JSN 2167 June 4, 2013 Response to Office Action (from prosecution history of ¿¿¿438 patent) | Mar 17, 2017 | EXHIBIT | PATENT OWNER |
JSN 2140 J&J Q2 2013 Earnings Call Transcript | Mar 17, 2017 | EXHIBIT | PATENT OWNER |
JSN 2141 J&J Q3 2013 Earnings Call Transcript | Mar 17, 2017 | EXHIBIT | PATENT OWNER |
JSN 2143 J&J Q1 2014 Earnings Call Transcript | Mar 17, 2017 | EXHIBIT | PATENT OWNER |
JSN 2145 J&J Q3 2014 Earnings Call Transcript | Mar 17, 2017 | EXHIBIT | PATENT OWNER |
JSN 2146 J&J Q4 2014 Earnings Call Transcript | Mar 17, 2017 | EXHIBIT | PATENT OWNER |
JSN 2147 J&J Q1 2015 Earnings Call Transcript | Mar 17, 2017 | EXHIBIT | PATENT OWNER |
JSN 2148 J&J Q2 2015 Earnings Call Transcript | Mar 17, 2017 | EXHIBIT | PATENT OWNER |
JSN 2151 Patent Owner Response in IPR2016-00286 | Mar 17, 2017 | EXHIBIT | PATENT OWNER |
JSN 2152 Declaration of Bindu Donovan | Mar 17, 2017 | EXHIBIT | PATENT OWNER |
JSN 2153 Declaration of Ivan Hofmann, filed on June 30, 2016 in Mylan Pharmaceuticals Inc. v. Janssen Oncology, Inc., IPR2016-01332 | Mar 17, 2017 | EXHIBIT | PATENT OWNER |
JSN 2154 Patent Owner Response in IPR2016-01332 | Mar 17, 2017 | EXHIBIT | PATENT OWNER |
JSN 2155 Butler affidavit and archive notarization | Mar 17, 2017 | EXHIBIT | PATENT OWNER |
JSN 2156 Sartor, ¿¿¿The Continuing Challenge of Hormone-Refractory Prostate | Mar 17, 2017 | EXHIBIT | PATENT OWNER |
JSN 2157 Sweeney, ¿¿¿ECOG 3805: CHAARTED ¿¿¿ ChemoHormonal Therapy versus Androgen Ablation Randomized Trial for Extensive Disease in Prostate Cancer,¿¿¿ | Mar 17, 2017 | EXHIBIT | PATENT OWNER |
JSN 2159 de Bono, J.S. et al., ¿¿¿Abiraterone and increased survival in metastatic prostate cancer,¿¿¿ New Engl. J. Med., 364:1995¿¿¿2005 (2011) | Mar 17, 2017 | EXHIBIT | PATENT OWNER |
EXPUNGED | Mar 17, 2017 | EXHIBIT | PATENT OWNER |
JSN 2162 Redacted deposition transcript of Paul A. Godley, taken by Patent Owner on March 7, 2017 | Mar 17, 2017 | EXHIBIT | PATENT OWNER |
JSN 2163 Sweeney, et al., ¿¿¿Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer,¿¿¿ NEJM, 373:737-746 (2015) | Mar 17, 2017 | EXHIBIT | PATENT OWNER |
JSN 2165 February 11, 2014 Notice of Allowance (from prosecution history of ¿¿¿438 patent) | Mar 17, 2017 | EXHIBIT | PATENT OWNER |
JSN 2166 June 2, 2014 Notice of Allowance (from prosecution history of
¿¿¿438 patent) | Mar 17, 2017 | EXHIBIT | PATENT OWNER |
JSN 2168 Zytiga Label (2011) | Mar 17, 2017 | EXHIBIT | PATENT OWNER |
Motion to Seal Under 37 C.F.R. 42.14 and 42.54 | Mar 17, 2017 | PAPER | PATENT OWNER |
Janssen Oncology, Inc.s Updated Exhibit List | Mar 17, 2017 | PAPER | PATENT OWNER |
Janssen Oncology Inc.s Patent Owner Response | Mar 17, 2017 | PAPER | PATENT OWNER |
Petitioner's Notice of Deposition of Richard Auchus, M.D., Ph.D. | Mar 16, 2017 | PAPER | PETITIONER |
Petitioner's Updated Mandatory Notices | Mar 2, 2017 | PAPER | PETITIONER |
Patent Owners Notice of Deposition of Paul A. Godley, M.D., Ph.D., MPP | Feb 28, 2017 | PAPER | PATENT OWNER |
Notice of Stipulation to Change Due Dates 1 and 2 | Feb 6, 2017 | PAPER | PETITIONER |
Patent Owners Notice of Deposition of Robert D. Stoner, Ph.D. | Feb 3, 2017 | PAPER | PATENT OWNER |
Patent Owners Objections to Evidence Pursuant to 37 C.F.R. 42.64(b)(1) | Feb 2, 2017 | PAPER | PATENT OWNER |
Petitioner's Objections to Patent Owner's Evidence | Feb 2, 2017 | PAPER | PETITIONER |
Patent Owners Notice of Designation of Additional Backup Counsel | Jan 27, 2017 | PAPER | PATENT OWNER |
Janssen Oncology, Inc.s Updated Mandatory Notices | Jan 27, 2017 | PAPER | PATENT OWNER |
Trial Instituted Document | Jan 19, 2017 | PAPER | BOARD |
Decision - Institution of Inter Partes Review - 37 C.F.R. 42.108 | Jan 19, 2017 | PAPER | BOARD |
Scheduling Order | Jan 19, 2017 | PAPER | BOARD |
Janssen Oncology Inc.s Surreply to Patent Owner Preliminary Response | Dec 22, 2016 | PAPER | PATENT OWNER |
Motion to Seal | Dec 22, 2016 | PAPER | PATENT OWNER |
Janssen Oncology Inc.s Surreply to Patent Owner Preliminary Response | Dec 22, 2016 | PAPER | PATENT OWNER |
2016/11/10 (DI 239)-Opinion on Markman Patent Claim Construction (DNJ) | Dec 19, 2016 | EXHIBIT | PATENT OWNER |
2016/14/10 (DI 240)-Order on Markman Patent Claim Construction (DNJ) | Dec 19, 2016 | EXHIBIT | PATENT OWNER |
Janssen Oncology, Inc.s Exhibit List | Dec 19, 2016 | PAPER | PATENT OWNER |
Order Conduct of the Proceeding | Dec 19, 2016 | PAPER | BOARD |
Petitioner's Reply to Patent Owner Preliminary Response | Dec 13, 2016 | PAPER | PETITIONER |
Declaration of Gopal Venkatesan | Dec 13, 2016 | EXHIBIT | PETITIONER |
Patent Owners Updated Mandatory Notices | Dec 9, 2016 | PAPER | PATENT OWNER |
BTG International Limiteds Power of Attorney | Dec 9, 2016 | PAPER | PATENT OWNER |
Order Authorizing Reply and Surreply to Patent Owner Preliminary Response | Dec 5, 2016 | PAPER | BOARD |
Decision - Motion for Pro Hac Vice Admission (Pritikin) | Dec 5, 2016 | PAPER | BOARD |
Decision - Motion for Pro Hac Vice Admission (Donovan) | Dec 5, 2016 | PAPER | BOARD |
Janssen Oncology, Inc.s Motion for Pro Hac Vice Admission of Bindu Donovan | Nov 28, 2016 | PAPER | PATENT OWNER |
Declaration of Bindu Donovan in Support of Motion to Appear Pro Hac Vice | Nov 28, 2016 | EXHIBIT | PATENT OWNER |
Janssen Oncology, Inc.s Motion for Pro Hac Vice Admission of David T. Pritikin | Nov 28, 2016 | PAPER | PATENT OWNER |
Declaration of David T. Pritikin in Support of Motion to Appear Pro Hac Vice | Nov 28, 2016 | EXHIBIT | PATENT OWNER |
Motion to Seal | Nov 16, 2016 | PAPER | PATENT OWNER |
Janssen Oncology Incs Preliminary Response | Nov 16, 2016 | PAPER | PATENT OWNER |
EXPUNGED | Nov 16, 2016 | EXHIBIT | PATENT OWNER |
EXPUNGED | Nov 16, 2016 | EXHIBIT | PATENT OWNER |
Public Version of 6/6/2016 ¿¿¿ 7/23/2016 Email Chain between J. Reda and V. Dhanorkar | Nov 16, 2016 | EXHIBIT | PATENT OWNER |
Standing Protective Order | Nov 16, 2016 | EXHIBIT | PATENT OWNER |
Janssen Oncology Incs Exhibit List | Nov 16, 2016 | PAPER | PATENT OWNER |
Janssen Oncology Incs Preliminary Response | Nov 16, 2016 | PAPER | PATENT OWNER |
Public Version of Declaration of Jennifer Reda | Nov 16, 2016 | EXHIBIT | PATENT OWNER |
Redline of Standing Protective Order | Nov 16, 2016 | EXHIBIT | PATENT OWNER |
Janssen Oncology, Incs Mandatory Notices | Aug 25, 2016 | PAPER | PATENT OWNER |
Janssen Oncology, Incs Exhibit List | Aug 25, 2016 | EXHIBIT | PATENT OWNER |
Janssen Oncology, Incs Power of Attorney | Aug 25, 2016 | PAPER | PATENT OWNER |
Janssen Oncology, Inc.s Exhibit List | Aug 25, 2016 | PAPER | PATENT OWNER |
Notice of Accepting Corrected Petition | Aug 17, 2016 | PAPER | BOARD |
Notice of Filing Date Accorded to Petition | Aug 16, 2016 | PAPER | BOARD |
Declaration of Paul A. Godley, M.D., Ph.D., MPP | Aug 16, 2016 | EXHIBIT | PETITIONER |
Declaration of Robert D. Stoner, Ph.D. | Aug 16, 2016 | EXHIBIT | PETITIONER |
Notice of Corrected Petition | Aug 16, 2016 | PAPER | PETITIONER |
Power of Attorney | Aug 10, 2016 | PAPER | PETITIONER |
USPN 8,822,438 | Aug 10, 2016 | EXHIBIT | PETITIONER |
Paul A. Godley Curriculum Vitae | Aug 10, 2016 | EXHIBIT | PETITIONER |
O'Donnell 2004 | Aug 10, 2016 | EXHIBIT | PETITIONER |
Sartor 1998 | Aug 10, 2016 | EXHIBIT | PETITIONER |
Tannock 2004 | Aug 10, 2016 | EXHIBIT | PETITIONER |
Trump 1989 | Aug 10, 2016 | EXHIBIT | PETITIONER |
Scholz 2005 | Aug 10, 2016 | EXHIBIT | PETITIONER |
Fossa 2001 | Aug 10, 2016 | EXHIBIT | PETITIONER |
Brassell 2005 | Aug 10, 2016 | EXHIBIT | PETITIONER |
Attard 2009 | Aug 10, 2016 | EXHIBIT | PETITIONER |
Ryan 2013 | Aug 10, 2016 | EXHIBIT | PETITIONER |
Danila 2010 | Aug 10, 2016 | EXHIBIT | PETITIONER |
Small 2001 | Aug 10, 2016 | EXHIBIT | PETITIONER |
USPN 5,604,213 | Aug 10, 2016 | EXHIBIT | PETITIONER |
Gerber 1990 | Aug 10, 2016 | EXHIBIT | PETITIONER |
Attard 2005 | Aug 10, 2016 | EXHIBIT | PETITIONER |
Harrison's Principles of Internal Medicine 2005 | Aug 10, 2016 | EXHIBIT | PETITIONER |
Tannock 1996 | Aug 10, 2016 | EXHIBIT | PETITIONER |
Harris 2002 | Aug 10, 2016 | EXHIBIT | PETITIONER |
Hellerstedt 2002 | Aug 10, 2016 | EXHIBIT | PETITIONER |
Costa-Santos 2004 | Aug 10, 2016 | EXHIBIT | PETITIONER |
Oh 2002 | Aug 10, 2016 | EXHIBIT | PETITIONER |
Berry 2002 | Aug 10, 2016 | EXHIBIT | PETITIONER |
FDA Press Release- May 19, 2004 | Aug 10, 2016 | EXHIBIT | PETITIONER |
Ryan 2011 | Aug 10, 2016 | EXHIBIT | PETITIONER |
Kelly 1993 | Aug 10, 2016 | EXHIBIT | PETITIONER |
Miller 1954 | Aug 10, 2016 | EXHIBIT | PETITIONER |
Tannock 1989 | Aug 10, 2016 | EXHIBIT | PETITIONER |
Scher 2005 | Aug 10, 2016 | EXHIBIT | PETITIONER |
File History of USPN 8,822,438 | Aug 10, 2016 | EXHIBIT | PETITIONER |
The Pharmacological Basis of Therapeutics 1990 | Aug 10, 2016 | EXHIBIT | PETITIONER |
Review of Medical Physiology 1979 | Aug 10, 2016 | EXHIBIT | PETITIONER |
Remington's Pharmaceutical Sciences 1980 | Aug 10, 2016 | EXHIBIT | PETITIONER |
Sartor 2011 | Aug 10, 2016 | EXHIBIT | PETITIONER |
Fisher 1993 | Aug 10, 2016 | EXHIBIT | PETITIONER |
Bearden 1977 | Aug 10, 2016 | EXHIBIT | PETITIONER |
Scher 2004 | Aug 10, 2016 | EXHIBIT | PETITIONER |
American Cancer Society | Aug 10, 2016 | EXHIBIT | PETITIONER |
ASCO- Sept. 8, 2014 | Aug 10, 2016 | EXHIBIT | PETITIONER |
Zytiga Label | Aug 10, 2016 | EXHIBIT | PETITIONER |
Zytiga Website | Aug 10, 2016 | EXHIBIT | PETITIONER |
Mayo Clinic- Hormone Therapy | Aug 10, 2016 | EXHIBIT | PETITIONER |
Drugs @ FDA | Aug 10, 2016 | EXHIBIT | PETITIONER |
FDA News Release- Dec. 10, 2012 | Aug 10, 2016 | EXHIBIT | PETITIONER |
Taxotere Prescribing Information 2004 | Aug 10, 2016 | EXHIBIT | PETITIONER |
Potter 1995 | Aug 10, 2016 | EXHIBIT | PETITIONER |
Fakih 2002 | Aug 10, 2016 | EXHIBIT | PETITIONER |
MacAdams 1986 | Aug 10, 2016 | EXHIBIT | PETITIONER |
Rajfer 1986 | Aug 10, 2016 | EXHIBIT | PETITIONER |
Santen 1983 | Aug 10, 2016 | EXHIBIT | PETITIONER |
Sonino 1987 | Aug 10, 2016 | EXHIBIT | PETITIONER |
Mauro 2003 | Aug 10, 2016 | EXHIBIT | PETITIONER |
Yamamoto 1994 | Aug 10, 2016 | EXHIBIT | PETITIONER |
Mayo Clinic- Prostate Cancer | Aug 10, 2016 | EXHIBIT | PETITIONER |
Kirby 2011 | Aug 10, 2016 | EXHIBIT | PETITIONER |
Patent Valuation: Improving Decision Making through Analysis 2012 | Aug 10, 2016 | EXHIBIT | PETITIONER |
Cowen & Company- J&J | Aug 10, 2016 | EXHIBIT | PETITIONER |
Wells Fargo Securities- J&J | Aug 10, 2016 | EXHIBIT | PETITIONER |
Zytiga Orange Book | Aug 10, 2016 | EXHIBIT | PETITIONER |
William Blair- Jan. 22, 2013 | Aug 10, 2016 | EXHIBIT | PETITIONER |
Zytiga Brochure | Aug 10, 2016 | EXHIBIT | PETITIONER |
Nasdaq- Aug. 5, 2014 | Aug 10, 2016 | EXHIBIT | PETITIONER |
Cowen & Company- July 2, 2012 | Aug 10, 2016 | EXHIBIT | PETITIONER |
William Blair- July 14, 2015 | Aug 10, 2016 | EXHIBIT | PETITIONER |
Industrial Market Structure and Economic Performance 1990 | Aug 10, 2016 | EXHIBIT | PETITIONER |
Attard 2008 | Aug 10, 2016 | EXHIBIT | PETITIONER |
Jevtana Website | Aug 10, 2016 | EXHIBIT | PETITIONER |
FDA News Release- June 17, 2010 | Aug 10, 2016 | EXHIBIT | PETITIONER |
Medivation Press Release- Sept. 10, 2014 | Aug 10, 2016 | EXHIBIT | PETITIONER |
UBS Research- Feb. 3, 2014 | Aug 10, 2016 | EXHIBIT | PETITIONER |
Wedbush- July 14, 2015 | Aug 10, 2016 | EXHIBIT | PETITIONER |
Barron's- RBC Capital Markets | Aug 10, 2016 | EXHIBIT | PETITIONER |
Credit Suisse- Dec. 11, 2012 | Aug 10, 2016 | EXHIBIT | PETITIONER |
UBS Zytiga Label Extended | Aug 10, 2016 | EXHIBIT | PETITIONER |
Bloomberg.com- Apr. 6, 2016 | Aug 10, 2016 | EXHIBIT | PETITIONER |
hurdle rate definition | Aug 10, 2016 | EXHIBIT | PETITIONER |
Robert D. Stoner Curriculum Vitae | Aug 10, 2016 | EXHIBIT | PETITIONER |
IMS Data- 2012-2015 | Aug 10, 2016 | EXHIBIT | PETITIONER |
EXPUNGED | Aug 10, 2016 | PAPER | PETITIONER |
EXPUNGED | Aug 10, 2016 | PAPER | PETITIONER |
Petition | Aug 10, 2016 | PAPER | PETITIONER |